Arcadia Investment Management Corp MI Trims Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Arcadia Investment Management Corp MI lessened its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 19.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,105 shares of the medical device company's stock after selling 3,585 shares during the quarter. Arcadia Investment Management Corp MI's holdings in DexCom were worth $1,032,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Proficio Capital Partners LLC bought a new stake in DexCom in the fourth quarter valued at approximately $5,812,000. Golden State Wealth Management LLC boosted its holdings in shares of DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares during the period. SBI Securities Co. Ltd. purchased a new stake in shares of DexCom during the fourth quarter worth about $49,000. Farther Finance Advisors LLC boosted its holdings in shares of DexCom by 29.3% during the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock worth $209,000 after purchasing an additional 702 shares during the period. Finally, Dynamic Advisor Solutions LLC boosted its holdings in shares of DexCom by 34.2% during the first quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock worth $357,000 after purchasing an additional 1,333 shares during the period. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $41,400.00. Following the completion of the sale, the executive vice president owned 95,102 shares of the company's stock, valued at approximately $7,874,445.60. The trade was a 0.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Nicholas Augustinos sold 3,672 shares of DexCom stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the sale, the director directly owned 33,411 shares of the company's stock, valued at approximately $2,766,430.80. This trade represents a 9.90% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 27,190 shares of company stock valued at $2,281,732. 0.32% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on DXCM shares. Mizuho started coverage on shares of DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price target on the stock. Robert W. Baird cut their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Canaccord Genuity Group lifted their price target on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Truist Financial assumed coverage on DexCom in a report on Monday, June 16th. They set a "buy" rating and a $102.00 target price on the stock. Finally, Barclays upped their target price on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Five analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $98.50.

DexCom Stock Up 0.7%

Shares of NASDAQ DXCM traded up $0.59 during midday trading on Thursday, hitting $85.46. The stock had a trading volume of 3,669,900 shares, compared to its average volume of 4,423,943. The business's 50 day moving average is $84.31 and its 200-day moving average is $79.97. The company has a market cap of $33.51 billion, a P/E ratio of 63.78, a PEG ratio of 1.81 and a beta of 1.44. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $117.19. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the prior year, the company posted $0.32 EPS. The company's quarterly revenue was up 12.5% on a year-over-year basis. As a group, analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.